Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Perispinal etanercept advances as a neurotherapeutic.

Tobinick E.

Expert Rev Neurother. 2018 Jun;18(6):453-455. doi: 10.1080/14737175.2018.1468253. Epub 2018 Apr 25. No abstract available.

PMID:
29695205
2.

Perispinal Delivery of CNS Drugs.

Tobinick EL.

CNS Drugs. 2016 Jun;30(6):469-80. doi: 10.1007/s40263-016-0339-2. Review.

3.

Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Ignatowski TA, Spengler RN, Tobinick E.

CNS Drugs. 2014 Dec;28(12):1207-13. doi: 10.1007/s40263-014-0212-0. No abstract available.

4.

Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E.

CNS Drugs. 2014 Aug;28(8):679-97. doi: 10.1007/s40263-014-0174-2.

5.

Immediate neurological recovery following perispinal etanercept years after brain injury.

Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN.

Clin Drug Investig. 2014 May;34(5):361-6. doi: 10.1007/s40261-014-0186-1.

PMID:
24647830
6.
7.

Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.

Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V.

CNS Drugs. 2012 Dec;26(12):1051-70. doi: 10.1007/s40263-012-0013-2.

PMID:
23100196
8.
9.

Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.

Tobinick E.

CNS Drugs. 2011 Feb;25(2):145-55. doi: 10.2165/11588400-000000000-00000.

PMID:
21254790
10.

Perispinal etanercept: a new therapeutic paradigm in neurology.

Tobinick E.

Expert Rev Neurother. 2010 Jun;10(6):985-1002. doi: 10.1586/ern.10.52. Review. Erratum in: Expert Rev Neurother. 2010 Jul;10(7):1232.

PMID:
20518613
11.

Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.

Tobinick E.

CNS Drugs. 2009 Sep;23(9):713-25. doi: 10.2165/11310810-000000000-00000. Review.

PMID:
19689163
12.

WITHDRAWN: PET Imaging Reveals that Etanercept Crosses the Blood-Cerebrospinal Fluid but not the Blood-Brain Barrier: Implications for Alzheimer's Disease.

McGeer PL, Tobinick E, Kornelsen R, McCormick S, Ferreira C, Lapi S, Ruth TJ.

J Alzheimers Dis. 2009 May 11. [Epub ahead of print]

PMID:
19433894
13.

The value of drug repositioning in the current pharmaceutical market.

Tobinick EL.

Drug News Perspect. 2009 Mar;22(2):119-25. doi: 10.1358/dnp.2009.22.2.1303818. Review.

PMID:
19330170
15.

Perispinal etanercept for neuroinflammatory disorders.

Tobinick E.

Drug Discov Today. 2009 Feb;14(3-4):168-77. doi: 10.1016/j.drudis.2008.10.005. Epub 2008 Dec 6. Review.

PMID:
19027875
17.

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.

Tobinick EL, Gross H.

BMC Neurol. 2008 Jul 21;8:27. doi: 10.1186/1471-2377-8-27.

18.

Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.

Tobinick EL.

Neurology. 2008 Apr 1;70(14):1222-3; author reply 1223. doi: 10.1212/01.wnl.0000307660.86647.7b. No abstract available.

PMID:
18378889
19.

Perispinal etanercept for treatment of Alzheimer's disease.

Tobinick E.

Curr Alzheimer Res. 2007 Dec;4(5):550-2. Review.

PMID:
18220520
20.

A critique of intradiscal administration for treatment of radiculopathy.

Tobinick EL.

Anesthesiology. 2008 Feb;108(2):334; author reply 335. doi: 10.1097/01.anes.0000300072.56020.10. No abstract available.

PMID:
18212586

Supplemental Content

Loading ...
Support Center